We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This retrospective cohort study evaluated outcomes in 34 patients with COVID-19 infection and concurrent hematological malignancies. Patients were stratified into survivors (n=23) and non-survivors (n=11) for comparative analyses. On review of baseline clinical and laboratory parameters at illness onset or on admission, only procalcitonin levels were significantly higher in non-survivors than survivors. The development of acute respiratory distress syndrome, an ECOG performance status ≥2, and qSOFA score ≥2 were associated with shorter survival.
This cohort study describes the presenting clinical and laboratory characteristics in a diverse group of hematological malignancy patients admitted with COVID-19 infection and provides data on outcomes in this vulnerable patient population.
– Curtis Lachowiez, MD
This abstract is available on the publisher's site.
The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020).
Survival Study of Hospitalized Patients With Concurrent Covid-19 and Haematological Malignancies
Br. J. Haematol 2020 May 07;[EPub Ahead of Print], F Martín-Moro, J Marquet, M Piris, BM Michael, AJ Sáez, M Corona, C Jiménez, B Astibia, I García, E Rodríguez, C García-Hoz, J Fortún-Abete, P Herrera, J López-Jiménez